Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 8;13:3081–3100. doi: 10.2147/CMAR.S292992

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Guo et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Cellular functions of P53 in ovarian cancer. P53 is activated to regulate the expression downstream genes to induce a series of cellular responses, such as cell cycle arrest, apoptosis, senescence, autophagy, DNA repair, angiogenesis, migration and metabolism in different types of extracellular and intracellular stress (eg, nutrient deprivation, telomere erosion, hypoxia, DNA damage, ribosomal stress, and oncogene activation). The primary treatment strategy for patients with ovarian cancer with P53 mutations is focused on restoring WT-P53 function to mutant P53, Blocking the interaction of WT P53 with MDM2/MDM4, and gene therapy with P53.